HHS releases $40M for chronic disease prevention

The U.S. Department of Health and Human Services (HHS) has made available approximately $40 million to strengthen and better coordinate activities within state and territorial health departments aimed at preventing chronic diseases and promoting health.

The initiative targets the nation’s five leading chronic disease-related causes of death and disability: heart disease, cancer, stroke, diabetes and arthritis.

The funds will support implementation of public health programs, surveillance of chronic diseases, translation of research into public health practice and development of tools, and resources for health workers and other leaders at the national, state and community levels, HHS added.

State and territorial health activities will focus on reducing age-adjusted mortality due to chronic diseases and reducing the prevalence of disabling chronic diseases. In addition, the initiative will work to improve health and quality of life by promoting environmental and policy changes related to nutrition, physical activity and clinical preventive services and by promoting education and management skills for people diagnosed with or at high risk for chronic diseases.

The Centers for Disease Control and Prevention (CDC) is expected to award funds for three-year coordinated statewide chronic disease programs to all 50 states and eight territories, with approximately $40 million available for the first 12-month budget period, the HHS stated.

As a critical requirement, successful grantees will create or update statewide plans that demonstrate coordinated approaches to addressing heart disease, cancer, stroke, arthritis and diabetes. The funds will also be used for nutrition, physical activity and anti-obesity programs, HHS stated.

Although tobacco use, a leading risk factor for chronic diseases, is not part of the initiative, other CDC statewide prevention programs will continue to address it, HHS added.

State and territorial health departments interested in submitting proposals can find more information here. The application deadline is July 22.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.